Yiwen Ling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yiwen Ling has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Rui Li
2 shared publicationsYing Zhao
2 shared publicationsZhuowen Chen
Department of Hematology, The First People's Hospital of Foshan, Foshan, China
2 shared publicationsFan Yang
1 shared publicationFen Huang
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publicationHongsheng Zhou
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in SSRN Electronic Journal
Global Disparities And Future Burden Of Hematologic Malignancies In Working-Age Population
Background: The global burden of hematologic malignancies in the working-age population (WAP; 15–64 years) remains insufficiently defined. We assessed burden, temporal trends, socioeconomic disparities, and future burden in this population.Methods: We analysed leukemia, non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and multiple myeloma (MM) using GLOBOCAN 2024 and GBD 2021. GLOBOCAN 2024 described current burden and GBD 2021 trends from 2000 to 2021. Outcomes included cases, deaths, age-standardised incidence and mortality rates, mortality-to-incidence ratio, and average annual percent change. The 2050 burden was projected using 2024 sex- and age-specific rates and projected populations.Findings: In 2024, hematologic malignancies accounted for 612,865 incident cases and 241,656 deaths in the WAP, with incidence and mortality rates of 11.1 and 4.3 per 100,000. Men had higher incidence and mortality than women. NHL contributed the most incident cases, whereas leukemia accounted for the largest share of deaths. Incidence increased strongly with HDI, mortality showed little association with HDI, and the mortality-to-incidence ratio was higher in lower-HDI settings. From 2000 to 2021, incidence and mortality declined overall, although trends varied across subtypes and settings. By 2050, incident cases and deaths were projected to increase to 727,521 and 318,028, with the largest increases in low-HDI countries.Interpretation:Hematologic malignancies impose a substantial and unequal burden in working-age adults. Despite mortality improvements, demographic change is expected to shift future growth toward low- and medium-HDI settings, highlighting the need to strengthen equitable diagnostic and treatment capacity.
- 23 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessGlobal Disparities And Future Burden Of Hematologic Malignancies In Working-Age Population
Background: The global burden of hematologic malignancies in the working-age population (WAP; 15–64 years) remains insufficiently defined. We assessed burden, temporal trends, socioeconomic disparities, and future burden in this population.Methods: We analysed leukemia, non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and multiple myeloma (MM) using GLOBOCAN 2024 and GBD 2021. GLOBOCAN 2024 described current burden and GBD 2021 trends from 2000 to 2021. Outcomes included cases, deaths, age-standardised incidence and mortality rates, mortality-to-incidence ratio, and average annual percent change. The 2050 burden was projected using 2024 sex- and age-specific rates and projected populations.Findings: In 2024, hematologic malignancies accounted for 612,865 incident cases and 241,656 deaths in the WAP, with incidence and mortality rates of 11.1 and 4.3 per 100,000. Men had higher incidence and mortality than women. NHL contributed the most incident cases, whereas leukemia accounted for the largest share of deaths. Incidence increased strongly with HDI, mortality showed little association with HDI, and the mortality-to-incidence ratio was higher in lower-HDI settings. From 2000 to 2021, incidence and mortality declined overall, although trends varied across subtypes and settings. By 2050, incident cases and deaths were projected to increase to 727,521 and 318,028, with the largest increases in low-HDI countries.Interpretation:Hematologic malignancies impose a substantial and unequal burden in working-age adults. Despite mortality improvements, demographic change is expected to shift future growth toward low- and medium-HDI settings, highlighting the need to strengthen equitable diagnostic and treatment capacity.
- 1 July 2021
- Published by Elsevier in Cancer Letters
- Vol. 510, 59-66
Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia
- 1 July 2021
- Published by Elsevier in Cancer Letters
- Vol. 510, 59-66
Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia
- 27 October 2020
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 45 (4) , 1443-1448
Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis
Prolonged survival and expanded treatment options in myeloma patients have led to adverse events associated with treatment getting increased attention. This systematic review and meta-analysis aimed to determine the incidence of ixazomib-associated cardiovascular adverse events (CVAEs) and to compare the rates of ixazomib-associated CVAEs and related therapies. CVAEs were defined as heart failure, hypertension, ischemia, and arrhythmia. All-grade and high-grade CVAEs and study characteristics were recorded. A total of 266 potentially relevant articles were identified, and 246 were excluded after review. Twenty studies of 1715 patients with multiple myeloma were thus considered in this study. The estimated rates of all-grade and high-grade ixazomib associated CVAEs were 11.2 and 3.7%, respectively. Subgroup analysis showed that median age ≥65 years, none phase 1 trial and combination regimen were associated with higher rates of high-grade ixazomib associated CVAEs. Ixazomib was association with increased high-grade CVAEs risk (RR = 1.679, 95% CI: 1.078-2.615, P = 0.022). Ixazomib was associated with a significant rate of high-grade CVAEs. Future studies are needed to identify patients at high risk for high-grade CVAEs.
- 27 October 2020
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 45 (4) , 1443-1448
Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis
Prolonged survival and expanded treatment options in myeloma patients have led to adverse events associated with treatment getting increased attention. This systematic review and meta-analysis aimed to determine the incidence of ixazomib-associated cardiovascular adverse events (CVAEs) and to compare the rates of ixazomib-associated CVAEs and related therapies. CVAEs were defined as heart failure, hypertension, ischemia, and arrhythmia. All-grade and high-grade CVAEs and study characteristics were recorded. A total of 266 potentially relevant articles were identified, and 246 were excluded after review. Twenty studies of 1715 patients with multiple myeloma were thus considered in this study. The estimated rates of all-grade and high-grade ixazomib associated CVAEs were 11.2 and 3.7%, respectively. Subgroup analysis showed that median age ≥65 years, none phase 1 trial and combination regimen were associated with higher rates of high-grade ixazomib associated CVAEs. Ixazomib was association with increased high-grade CVAEs risk (RR = 1.679, 95% CI: 1.078-2.615, P = 0.022). Ixazomib was associated with a significant rate of high-grade CVAEs. Future studies are needed to identify patients at high risk for high-grade CVAEs.